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Sphingosine 1-phosphate (S1P) is a bioactive lipid involved in the regulation of biological
processes such as proliferation, differentiation, motility, and survival. Here we review the
role of S1P in the biology and homeostasis of skeletal muscle. S1P derives from the
catabolism of sphingomyelin and is produced by sphingosine phosphorylation catalyzed
by sphingosine kinase (SK). S1P can act either intracellularly or extracellularly through
specific ligation to its five G protein-coupled receptors (GPCR) named S1P receptors
(S1PR). Many experimental findings obtained in the last 20 years demonstrate that
S1P and its metabolism play a multifaceted role in the regulation of skeletal muscle
regeneration. Indeed, this lipid is known to activate muscle-resident satellite cells,
regulating their proliferation and differentiation, as well as mesenchymal progenitors such
as mesoangioblasts that originate outside skeletal muscle, both involved in tissue repair
following an injury or disease. The molecular mechanism of action of S1P in skeletal
muscle cell precursors is highly complex, especially because S1P axis is under the control
of a number of growth factors and cytokines, canonical regulators of skeletal muscle
biology. Moreover, this lipid is crucially involved in the regulation of skeletal muscle
contractile properties, responsiveness to insulin, fatigue resistance and tropism. Overall,
on the basis of these findings S1P signaling appears to be an appealing pharmacological
target for improving skeletal muscle repair. Nevertheless, further understanding is required
on the regulation of S1P downstream signaling pathways and the expression of S1PR. This
article will resume our current knowledge on S1P signaling in skeletal muscle, hopefully
stimulating further investigation in the field, aimed at individuating novel molecular targets
for ameliorating skeletal muscle regeneration and reducing fibrosis of the tissue after a
trauma or due to skeletal muscle diseases.
Keywords: sphingosine 1-phosphate, skeletal muscle, skeletal muscle progenitors, satellite cells, muscle
regeneration, insulin responsiveness, myoblasts, skeletal muscle metabolism
INTRODUCTION ON SKELETAL MUSCLE
Skeletal muscle represents about 40% of the entire body weight.
The functional and structural constituent of skeletal muscle is
the myofiber, multinucleated cell that derives from the fusion
of mesodermal precursors named myoblasts. Each myofiber is
delimited by the basal lamina and is composed of myofibrils of
actin and myosin, organized as a sarcomere, the functional unit
of skeletal muscle. On the basis of their physiological features,
muscle fibers can be distinguished into slow contracting, fatigue
resistant fibers and fast contracting, fatigue sensitive fibers.
Skeletal muscle exerts physiological roles relevant for the
control of body metabolism since it accounts for bloodstream
aminoacid disposal in fasting condition and for removing excess
glucose by favoring glycogen accumulation in response to insulin
after a meal. Moreover, by releasing heat during force generation
it contributes to body temperature maintenance.
During development, the number of myofibers following
myoblast fusion increase, while in adulthood skeletal muscle
is stable beyond infrequent fusion of satellite cells to compen-
sate physiologic turnover. Following a trauma, injury, or disease
skeletal muscle has indeed the potential to regenerate thanks to an
highly orchestrated process driven by satellite cells and their niche
(Yin et al., 2013).
Satellite cells are the resident stem cells of the skeletal mus-
cle, located between the basal lamina of muscle fibers and the
plasma membrane. Even if it is known that satellite cells derive
from somites, their exact progenitor cell is still elusive. Satellite
cells are quiescent in adult skeletal muscle and represent 3–6%
of the total nuclei in the fiber (Tedesco et al., 2010). When acti-
vated, they start proliferating and can generate in few days a
large number of myofibers: it has been demonstrated that few
as seven satellite cells transplanted into irradiated muscle of dys-
trophic immune-deficient mice led to an increase of 100 new
muscle fibers with thousands of myonuclei (Collins et al., 2005).
Activated satellite cells cultured on plastic collagen-coated dishes
are named “satellite cell-derived myoblasts” or myogenic precur-
sor cells distinct from a functional and molecular point of view
from freshly isolated satellite cells, possibly due to the absence
of their niche (Dhawan and Rando, 2005; Pallafacchina et al.,
2010). Stem cells can self-renew in asymmetric and symmetric
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division. In asymmetric division the parental stem cell divides
into two different daughter cells, one remains stem cell, the
other fated to differentiate. In symmetric division the parental
stem cell gives rise to two daughter stem cells of equal stemness.
Satellite cells can undergo asymmetric and symmetric division
and non-canonical Wnt signaling plays a role in the regulation
of self-renewal (Chargé and Rudnicki, 2004; Troy et al., 2012).
A number of satellite cell markers have been identified such as
Pax3, Pax7, Myf5, M-cadherin, cMet, CD34, CXCR4, although
they are not unique and there is not complete correspondence
between mouse and human (Yin et al., 2013).
In addition to satellite cells, other skeletal muscle progeni-
tors including pericytes (Dellavalle et al., 2011), mesoangioblasts
(Minasi et al., 2002), bone marrow stem cells (LaBarge and Blau,
2002), and interstitial cells (Mitchell et al., 2010) located out-
side the myofiber, have been demonstrated to have the ability to
regenerate skeletal muscle, although to a negligible extent com-
pared with satellite cells (Judson et al., 2013). Nowadays there is
a great interest in understanding the molecular mechanisms of
skeletal muscle regeneration since it will permit the development
of cell therapies for skeletal muscle diseases such as muscular dys-
trophies (Tedesco et al., 2010), a group of inherited disorders
characterized by progressive muscle wasting and depletion of the
satellite cell pool after extensive cycle of regeneration (Carlson
and Conboy, 2007; Chakkalakal et al., 2012; Pannérec et al., 2012;
García-Prat et al., 2013). Muscular dystrophies are indeed very
difficult to treat because skeletal muscle is composed of hundreds
of millions of post-mitotic nuclei.
SPHINGOLIPID METABOLISM AND SPHINGOSINE
1-PHOSPHATE FORMATION
During the last 20 years, sphingolipids, initially considered struc-
tural component of eukaryotic membranes, have been high-
lighted as a crucial molecules involved in the regulation of
fundamental biological processes such as cell migration, sur-
vival, proliferation, differentiation, adhesion, and implicated in
inflammation, tumorigenesis, immunity and vascular develop-
ment (Hannun and Obeid, 2008; Maceyka et al., 2012). In this
review we will focus on the role of the bioactive sphingolipid sph-
ingosine 1-phosphate (S1P), its metabolism, its receptors and its
cross-talk with growth factors and cytokines in skeletal muscle
biology and physiology.
Ceramide, a largely known effector of stress responses
(Zeidan and Hannun, 2010) plays a central role in sphingolipid
metabolism. The first step in the de novo pathway of ceramide
production is the condensation reaction catalyzed by the enzyme
serine palmitoyl transferase to form dihydrosphingosine from
palmitoyl-CoA and the aminoacid serine. Dihydrosphingosine is
then acylated by the action of ceramide synthase to dihydroce-
ramide which is then desaturated to ceramide by the enzyme
ceramide desaturase. Ceramide can be also generated by the
breakdown of membrane sphingomyelins, catalyzed by the action
of various sphingomyelinases or by the degradation of complex
glycosphingolipids by the action of glucosylceramidases. The acyl
chain of ceramide is then removed by the action of ceramidases
and the amino alcohol sphingosine is produced. Sphingosine can
be reconverted to ceramide by the action of ceramide synthase
via the so-called salvage pathway mechanism. Sphingosine can
be phosphorylated in an ATP-dependent manner to S1P by the
enzymes sphingosine kinase (SK) 1 and SK2. S1P can be dephos-
phorylated back to sphingosine by the action of two specific
S1P phosphatases and by three lipid phosphate phosphatases.
Alternatively, S1P is irreversibly degraded by the action of S1P
lyase (SPL) into hexadecenal and phosphoethanolamine.
SK1 is a cytosolic enzyme which contains residues that bind
acidic phospholipids that contribute to its intracellular localiza-
tion (Stahelin et al., 2005). Numerous agonists have been reported
to be able to activate SK1, including growth factors, hormones,
cytokines, and G protein-coupled receptors (GPCR) ligands.
Following ERK phosphorylation at serine 225, SK1 translocates
to plasma membrane where its substrate sphingosine is localized
(Pitson et al., 2003). The regulation of SK localization within
the cell is the major mechanism by which the enzyme affects
sphingolipid metabolism since only minute increases in the activ-
ity are reported following stimulation with different agonists.
Once produced, S1P, precisely partitioned into plasmamembrane
microdomains, is then locally released to activate S1P receptors
(S1PR) acting in autocrine and/or paracrinemanner. This process
is called “inside-out” signaling. Different transporters have been
implicated in S1P export such as the ATP binding cassette trans-
porters, ABCC1 (Mitra et al., 2006), ABCA1 (Sato et al., 2007),
ABCG2 (Takabe et al., 2010), and more recently the specific spin-
ster 2 (Spns2) (Kawahara et al., 2009); however, no information
on their role in skeletal muscle is presently available. Additionally,
since the chloride ion channel CFTR has a role in mediating S1P
transport and signaling in heart (Meissner et al., 2012) and lack of
CFTR causes functional alteration in skeletal muscle (Divangahi
et al., 2009), it will be of interest to further investigate this issue.
In contrast to SK1, SK2 is localized in several intracellu-
lar compartments such as endoplasmic reticulum, nucleus, and
mitochondria. Even if it is known that ERK-mediated phospho-
rylation is required for SK2 activation, the exact mechanism of
SK2 regulation is still elusive. While SK1-formed S1P is rapidly
exported outside the cell through the transporters localized at
the plasma membrane, SK2-produced S1P at the level of mito-
chondria and endoplasmic reticulum is likely rapidly degraded or
dephosphorylated by SPL and phosphatases present in close prox-
imity. Therefore, SK2 has, in respect to SK1, an enhanced ability
to recycle sphingoid bases for ceramide synthesis (Le Stunff et al.,
2007). Compared to SK1, less is known about the mechanism of
SK2 regulation. It has been reported that EGF and phorbol ester
(Hait et al., 2007) activates the enzyme. Moreover, under hypoxia
an increase in SK2 protein level and enzymatic activity has been
demonstrated (Schnitzer et al., 2009).
Bioactive S1P can either function as ligand of a family of GPCR
named S1PR and through intracellular targets, some of them
recently identified. There are five specific S1PR, S1PR1−5, all with
low nMKd values. Since these receptors couple to multiple α sub-
units of heterotrimeric G proteins and are differentially expressed
in diverse cell types and tissues, they induce the activation of
different downstream targets such as ERK, Rac, Rho, JNK, adeny-
lyl cyclase, phospholipase C, thus evoking distinct, sometimes
overlapping or opposite, biological responses. While S1P1−3 are
ubiquitously expressed, S1P4 and S1P5 are tissue specific, being
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mostly expressed in the lymphoid and central nervous system,
respectively (Spiegel and Milstien, 2003). S1P1 plays a crucial role
in angiogenesis, indeed its deletion in mice is embryonic lethal
due to hemorrhage for incomplete vascular maturation since per-
icytes do not migrate to the nascent endothelial tubes (Liu et al.,
2000). S1P2 null mice are deaf indicating that S1P2 is required for
proper development of the auditory and vestibular systems (Kono
et al., 2007). Unlike S1P1 null mice, S1P3 deletion in mice do not
generate any obvious phenotype.
A number of cytokines and growth factors have been reported
to regulate the expression of the enzymes of S1P metabolism
(Lebman and Spiegel, 2008). In addition to S1PR transactivation
following stimulation with growth factors and cytokines, S1P lig-
ation to its receptors also transactivates growth factor tyrosine
kinase receptors. This mutual functional cross-talk regulates fun-
damental biological processes such as growth, differentiation, and
motility in various cell types.
Many data reported in literature support that the intracel-
lular role of S1P is that of counteracting the biological actions
of ceramide in the so-called “rheostat model” where the S1P-
forming enzyme SK plays a crucial role. Although S1P was discov-
ered as intracellular messenger (Olivera and Spiegel, 1993), only
recently, some of the intracellular targets of S1P have begun to
be identified. SK2 present in the nucleus has been demonstrated
to form a complex with histone H3 and histone deacetylases
(HDACs). SK2-produced S1P binds to and inhibits HDAC1/2,
thus contributing to the regulation of the epigenetic control of
specific genes (Hait et al., 2009). Instead, tumor necrosis factor
receptor associated factor 2 (TRAF2), a crucial component in
NFkB signaling triggered by TNFα, has been reported as intra-
cellular target for S1P produced by SK1. Indeed, S1P formed by
SK1, which is known to co-localize with TRAF2 (Xia et al., 2002)
has been found to bind to TRAF2 and stimulate its dormant
ubiquitin ligase activity upstream of NFkB activation (Alvarez
et al., 2010). Moreover, SK2-produced S1P in the mitochon-
drion binds in vitro and in vivo to prohibitin 2, a conserved
protein that regulates mitochondrial assembly and function. SK2
null mice display reduced mitochondria respiration, suggesting
that S1P/prohibitin 2 interaction is physiologically relevant for
mitochondrial function (Strub et al., 2011).
BIOLOGICAL ROLE OF S1P IN SATELLITE CELLS
A number of recently published papers support the role of S1P
axis in the regulation of muscle resident satellite cell biology.
Indeed, S1P was identified as one of the few extracellular cues
capable of stimulating quiescent satellite cells to enter the cell
cycle (Nagata et al., 2006). Inhibition of S1P formation by incu-
bation with the SK inhibitor dimethylsphingosine (DMS) signifi-
cantly reduced satellite cell activation in response to mitogen and
impaired satellite cell-driven muscle regeneration in response to
in vivo damage induced by cardiotoxin. Moreover, the authors
showed that the degradation of the sphingomyelin inner leaflet
pool accounts for the generation of S1P, then regulating satellite
cell activation. In line with these findings, Calise et al. have char-
acterized the S1PR involved in the mitogenic effect of S1P and the
underlyingmechanism of action (Calise et al., 2012). Satellite cells
express 4 out of 5 S1PR, S1PR1−4, being S1P3 the most expressed
one in growing conditions. Indeed, by utilizing specific receptor
antagonist and siRNA silencing, S1P was demonstrated to stim-
ulate labeled thymidine incorporation by engagement of S1P2
and S1P3 in a PI3K-dependent manner. Moreover, the authors
demonstrated also that S1P positively stimulates satellite cell
migration via specific ligation to S1P1 and S1P4. This latter find-
ing, for the first time, highlights the role of S1P4 in skeletal muscle
beyond its already established relevance in lymphoid tissue. Very
recently it has been shown that S1P3 suppresses cell cycle progres-
sion in murine satellite cells (Fortier et al., 2013). Indeed, satellite
cells isolated from S1P3 null mice showed enhanced ex-vivo pro-
liferation, while retrovirally-mediated constitutive expression of
S1P3 inhibited cell proliferation of satellite cells.
BIOLOGICAL ROLE OF S1P IN OTHER SKELETAL MUSCLE
PROGENITORS
Skeletal muscle regeneration, besides being due to the presence of
resident satellite cells in skeletal muscle, is carried on, in vivo or
after transplantation, by progenitors that originates outside the
basal lamina such as pericytes, interstitial cells, mesoangioblasts,
and adipose tissue-derived mesenchymal stem cells (ASC). The
characterization of the molecular mechanism of the myogenic
potential of these progenitors is nowadays of great interest since
such kind of knowledge could be applied in the development of
cell therapies for diseases characterized by skeletal muscle degen-
eration. S1P axis has been shown to play a role in the regulation of
fundamental biological parameters such as proliferation, migra-
tion and differentiation of multipotent adult stem cells such as
mesoangioblasts (Donati et al., 2007a, 2009, 2011), and ASC
(Nincheri et al., 2009).
Mesoangioblasts (Minasi et al., 2002) are vascular progenitors
associated with dorsal aorta in avian and mammalian species,
that when transplanted in vivo give rise to multiple mesoder-
mal cell types such as osteoblasts, chondrocytes, and muscle
cells. They show an extensive ability of in vitro self-renewing
and upon injection, are able to cross the endothelial barrier
and can fuse with muscle fibers, contributing to their regen-
eration. Indeed, mesoangioblasts have been demonstrated to
contribute to muscle regeneration in animal models of muscu-
lar dystrophy such as α-sarcoglycan null mice (Sampaolesi et al.,
2003) and golden retriever dystrophic dogs (Sampaolesi et al.,
2006). S1P1−3 were detected at mRNA level in mesoangioblasts
with S1P3 the predominantly expressed receptor. S1P has been
demonstrated to potently stimulate mesoangioblast proliferation
in S1P2-dependent manner (Donati et al., 2007a). Moreover,
the bioactive sphingolipid successfully contrasted the apoptosis
induced by different apoptogenic stimuli, without engagement
of S1PR. It is important to note that pre-treatment of mesoan-
gioblasts with S1P enhanced their survival when injected in the
tibialis anterior muscle of α-sarcoglycan null dystrophic mice,
further supporting a role for the sphingolipid in preventing pro-
grammed cell death. Moreover, the SK/S1P axis was found to be
involved in the anti-apoptotic action exerted by TGFβ in these
cells (Donati et al., 2009). RNA silencing or overexpression of
dominant negative mutant form of SK1 highlighted a key role
of SK1 but not SK2 in mediating TGFβ pro-survival action. The
cytokine increased SK activity and up-regulated SK1 expression
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which was down-regulated by the apoptotic challenge. A succes-
sive study demonstrated the crucial role of the cross-talk between
S1P and TGFβ in the biology of mesoangioblasts. Data obtained
by a cDNA microarray study, validated by real time PCR and
immunofluorescence microscopy approaches, highlighted that
S1P exerts a strong differentiating action of mesoangioblasts
toward smooth muscle cells. Interestingly it was shown that S1P
axis was required by TGFβ to exert its differentiating activity
toward smooth muscle on mesoangioblasts. The study individ-
uated also the transcription factor GATA6 as a novel player in
the complex transcriptional regulation of mesoangioblast dif-
ferentiation to smooth muscle. S1P up-regulated the expression
of GATA6 which was responsible for the enhanced expression
of smooth muscle contractile proteins. By specific silencing of
GATA6 it was demonstrated that the transcription factor was crit-
ical also in the pro-differentiating activity of TGFβ (Donati et al.,
2011).
ASC are mesenchymal stem cells able to differentiate into dif-
ferent mesodermal lineages (Chamberlain et al., 2007). Being
relatively easy to isolate and able to rapidly proliferate in vitro,
these cells are promising in the development of cell therapy
tools. S1P administration to ASC up-regulated the expression of
smooth muscle protein markers, induced the appearance of cal-
cium currents and of actin cytoskeleton reorganization typical of
smooth muscle cells. S1P differentiating action was found to rely
on S1P2 engagement while S1P3 role was less critical (Nincheri
et al., 2009).
BIOLOGICAL ROLE OF S1P SIGNALING AXIS IN MYOBLASTS
C2C12 cell line is a subclone of the parental C2 cells which dif-
ferentiate into myotubes in appropriate culture condition, after
serum deprivation (Yaffe and Saxel, 1977; Blau et al., 1985). This
model is therefore widely used as a tool to study the myogenic
differentiation process and the involved molecular mechanisms.
C2C12 cells express 4 out of 5 S1PR, S1P1−4, being S1P1 the
most expressed receptor (Meacci et al., 2003; Bruni and Donati,
2013; Donati et al., 2013). Earlier reports showed that in C2C12
cells exogenous S1P activates a number of signaling pathways:
indeed it induced a rapid stimulation of phospholipase D activity
(Meacci et al., 1999) and a transient and rapid membrane associ-
ation of RhoA (Meacci et al., 2000) in a PKC-dependent manner.
Moreover, the bioactive lipid was demonstrated to induce Ca2+
mobilization in a S1P2/3-dependent manner (Meacci et al., 2002).
Interestingly, differentiation of C2C12 myoblasts into myotubes
was accompanied by deep changes in expression of S1PR. Indeed,
S1P2 was down-regulated while S1P3 was up-regulated in dif-
ferentiated cells (Meacci et al., 2003), suggesting that S1P2 plays
a role in myoblasts but is dispensable in myotubes. The crucial
role of S1P2 in myogenic differentiation of C2C12 myoblasts was
demonstrated in a later study, where S1P was shown to exert
via this receptor subtype a negative action on serum-induced
proliferation and to act as a potent inducer of differentiation
(Donati et al., 2005). The role of S1P2 was demonstrated by phar-
macological and genetic approaches. The involvement of S1P2
in myogenic differentiation was further confirmed by a subse-
quent report where the compound K6PC5, a synthetic deriva-
tive of ceramide, previously shown to induce SK1 activation
in keratinocytes (Kwon et al., 2007), stimulated myoblast dif-
ferentiation in a S1P2-dependent manner (Bernacchioni et al.,
2011).
S1P2 was also identified as the responsible for the inhibitory
effect on myoblast directional motility and insulin like growth
factor-1 (IGF-1)-induced chemotaxis exerted by S1P in C2C12
myoblasts (Becciolini et al., 2006), in line with the anti-migratory
action of this receptor demonstrated in other cell systems
(Arikawa et al., 2003; Lepley et al., 2005). In this study was also
established the involvement of RhoA activation in the negative
regulation of cell motility.
During muscle regeneration, following satellite cell activation
andmigration to the site of lesion, inhibition of myoblast motility
and differentiation into myotubes takes place in a highly orches-
trated manner. In view of its role as muscle pleiotropic regulatory
molecule, S1P exerts a dual role on cell migration, stimulating at
first migration of activated satellite cells (Calise et al., 2012) and
then inhibiting that of C2C12 myoblasts (Becciolini et al., 2006),
subsequently to a timely remodeling of S1PR expression pattern,
thus favoring skeletal muscle repair (Table 1).
During in vitro differentiation of C2C12 myoblasts, a small
population of cells, named reserve cells remains undifferentiated,
thus resembling quiescent satellite cells (Yoshida et al., 1998).
The analysis of the role of S1PR in regulating cell proliferation
highlighted that in reserve cells, S1P, via specific coupling to
S1P1, stimulates cell proliferation similarly to what demonstrated
in satellite cells but differently from what shown in myoblasts
(Rapizzi et al., 2008). In view of the finely regulated expression
of S1PR during commitment and differentiation of myogenic
precursors which drive different biological outcomes of the bioac-
tive lipid, future studies are required to characterize the specific
molecular mechanisms regulating the differential expression of
S1PR and their coupling.
Successive studies have elucidated some downstream events
implicated in the promyogenic effect of the sphingolipid. Indeed,
exogenous addition of S1P to C2C12 myoblasts up-regulated the
expression of the gap junctional protein connexin-43 (Squecco
et al., 2006), and the transient receptor potential cation channel, a
component of the stretch activated channel (Formigli et al., 2007;
Meacci et al., 2010).
The role of S1P metabolism, with special attention to SK,
the enzyme responsible for S1P production, in the regulation
of C2C12 cell growth and differentiation has been highlighted.
Indeed, the expression of SK1 was found to be enhanced in dif-
ferentiating myoblasts (Meacci et al., 2008). Additionally, when
overexpressed, SK1 was responsible for a significative reduction of
Table 1 | Role of sphingosine 1-phosphate on cell proliferation and
migration in myoblasts and activated satellite cells.
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myoblast proliferation rate, while it enhanced the appearance of a
differentiated phenotype and the expression of myogenic marker
proteins. On the contrary, when SK1 was silenced or a dominant
negative mutant form of the enzyme was overexpressed, myoblast
proliferation was increased and myogenic differentiation rate was
reduced. The role of S1P2 in myogenic differentiation was also
confirmed in this study, since when the receptor was silenced,
the pro-myogenic action of SK1 overexpression was abolished.
Therefore, although in the literature SK1 has been reported to
have a mitogenic role (Maceyka et al., 2012), in myoblasts this
enzyme displays an opposite biological effect.
As outlined above, SK activity is under the control of a variety
of growth factors, cytokines, neurotransmitters, and hormones
(Maceyka et al., 2012), which leads to the existence of func-
tional cross-talks further complicating S1P signaling. Following
the demonstration of the role of SK1 in myogenesis, several
reports have shown that a number of growth factors and cytokine,
known as crucial regulator of skeletal muscle biology, co-opt S1P
signaling (Figures 1, 2). The pro-inflammatory cytokine TNFα,
which is critically implicated in the remodeling of skeletal muscle
(Li and Schwartz, 2001), at low doses has been shown to translo-
cate SK1 to membrane and, via S1P2 engagement, to stimulate
C2C12 myoblast differentiation (Donati et al., 2007b). Notably,
IGF-1, one of the most important physiological regulator of skele-
tal muscle regeneration (Pedersen and Febbraio, 2012), activates
both SK isoforms, SK1 and SK2, and via specific transactivation
of S1P2, exerts its myogenic action (Bernacchioni et al., 2012).
Moreover, IGF-1 is also responsible for SK-dependent transacti-
vation of S1P1 and S1P3 that in turn reduce the mitogenic effect
of the growth factor.
Interestingly, also platelet derived growth factor (PDGF),
another growth factor relevant for the biology and the repair
of skeletal muscle (Husmann et al., 1996), exerts a nega-
tive role on myoblast proliferation via selective SK1 acti-
vation and S1P1 transactivation. Moreover, S1P inside-out
signaling and S1P1 engagement appear to be necessary for
conveying of PDGF-induced chemotactic action. It is impor-
tant to note that despite the importance of S1P1 engagement
in the biological action of IGF-1 and PDGF in myoblasts,
S1P1 down-regulation or pharmacological inhibition did not
affect the biological responses evoked by exogenously added
S1P (Donati et al., 2005; Becciolini et al., 2006). This observation
suggests that spatial regulation of S1P generation inside the cell is
critical for determining the subset of engaged receptors, its final
biological outcomes and that S1P1 is not freely accessible to its
ligand from outside the cell. Indeed, structural evidence indicated
that ligand binding to S1P1 occurs by initial delivery of S1P to the
exterior portion of membrane followed by a lateral diffusion into
the receptor binding pocket (O’Sullivan and Dev, 2013).
SK/S1P axis is also exploited by TGFβ to transmit its pro-
fibrotic, anti-differentiating action in C2C12 myoblasts (Cencetti
et al., 2010). Unfortunately, during muscle regeneration, the
transdifferentiation of myoblasts and muscle resident fibroblasts
into myofibroblasts give rise to muscle fibrosis that reduces mus-
cle contractile properties and impairs full muscular recovery.
The cytokine TGFβ plays a crucial role in the promotion of the
fibrosis onset and in the inhibition of myogenesis (McLennan
and Koishi, 2002); importantly, the inhibition of TGFβ signaling
pathway has been shown to ameliorate the chronic degenera-
tive fibrosis of dystrophic muscles (Cohn et al., 2007). Indeed,
TGFβ induced a Smad-dependent up-regulation of SK1 expres-
sion and activation, which, in contrast to what expected on the
basis of the previously demonstrated SK1 role in myogenesis
(Donati et al., 2005; Meacci et al., 2008), redirected the final
S1P biological outcome from being promyogenic to profibrotic
since the cytokine induced also a profound remodeling of S1PR
expression pattern, at least at mRNA levels. This was respon-
sible for readdressing the pro-myogenic role mediated through
S1P2 to a pro-fibrotic role mediated by S1P3, which following
TGFβ administration, became the most expressed receptor. These
data support the concept that interfering with S1P3 signaling
might favor therapeutic intervention to reduce skeletal muscle
fibrosis.
Very recently a new signaling pathway related to TGFβ-
induced apoptosis has been identified in C2C12 myoblasts
which relies on Rho kinase-2 stimulation, subsequent to SMAD-
dependent TGFβ-induced S1P4 up-regulation and transactiva-
tion via SK2 (Cencetti et al., 2013). This finding supports the
notion that S1P4 is up-regulated by TGFβ and is relevant for the
apoptotic action of the cytokine in skeletal muscle.
BIOLOGICAL ROLE OF S1P IN SKELETAL MUSCLE
Skeletal muscle has the ability to adapt to different physiologi-
cal and pathological conditions since it displays a high degree of
FIGURE 1 | Schematic diagram of the biological actions evoked by S1PR transactivation by some growth factors in C2C12 myoblasts.
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FIGURE 2 | Schematic diagram of the biological actions evoked by S1PR transactivation by some cytokines in C2C12 myoblasts.
plasticity. The size of skeletal muscle fibers results from a bal-
ance between protein synthesis and degradation, and varies as
a consequence of physiological and pathological circumstances.
The increase of individual muscle fibers, i.e., hypertrophy, occurs
when protein synthesis exceeds protein degradation in response
to hormonal stimulation or mechanical overload. A reduction
in skeletal muscle mass and fiber size, i.e., atrophy, occurs in
response to catabolic hormonal stimulation, denervation, aging,
cancer, bed rest, and starvation (Schiaffino et al., 2013). S1P has
been reported to be involved in the regulation of some physio-
logical properties of skeletal muscle such as muscle contractility,
fatigue, and adaptation.
Indeed, S1P has been shown to affect the excitation-
contraction coupling in fibers isolated from murine extensor
digitorum longus (EDL). The bioactive lipid modulated the volt-
age threshold and the inward calcium current through the dihy-
dropyridine receptor in a S1P3-dependent manner although the
experiments were carried out in the presence of the unspecific
receptor antagonist suramin (Bencini et al., 2003).
Zanin et al. (2008) has demonstrated a trophic role for S1P in
a rat model of denervation atrophy. S1P, delivered to the muscle
through a mini osmotic pump, significantly reduced the negative
effects of denervation on muscle mass and cross sectional area
(CSA) after 7 and 14 days of regeneration. Moreover, despite its
established anti-proliferative and pro-apoptotic role (Bruni and
Donati, 2008), also sphingosine exerted a trophic effect, likely due
to its conversion to S1P catalyzed by SK, as suggested by the abol-
ishment of the positive action of the sphingolipid in the presence
of DMS. Moreover, by real time PCR, S1P1, and S1P3 were found
to be selectively expressed, and subjected to down-regulation
upon denervation.
The decline in the ability of skeletal muscle to generate force
after a strenuous exercise is named muscle fatigue. The process
is reversible and depends on multiple factors such as the inten-
sity and the duration of the contraction and the type of fibers
of the muscles. Exogenous S1P has been found able of reduc-
ing muscle fatigue of EDL muscles (Danieli-Betto et al., 2005).
Interestingly, administration of sphingosine significantly dimin-
ished the tension decline. Since sphingosine effect was reduced
in the presence of the unselective SK inhibitor DMS, it was
deduced that the mechanism of action implicates S1P production
through SK activation. Indeed the effect of sphingosine, but not
that of S1P, was abolished in the absence of Ca2+, suggesting a
Ca2+-dependent mechanism of activation of SK.
The role of S1P signaling in skeletal muscle regeneration has
been firstly demonstrated inmouse and rat models after myotoxic
injury induced by bupivacaine (Danieli-Betto et al., 2010). The
administration of S1P after muscle damage induced a significant
increase of CSA while the neutralization of circulating S1P by
administration of an anti-S1P antibody abolished fiber growth.
Western blotting analysis of S1PR expression in muscle lysates
during rat soleus regeneration showed dynamic changes of S1PR
at protein level suggesting their putative role during regenera-
tion. The S1P-induced increase of regenerating fiber growth was
inhibited by a selective S1P1 agonist and augmented by a selective
S1P1/3 antagonist, supporting a negative role of S1P1 and a posi-
tive role of S1P3 in the early phases of regeneration. In contrast, a
very recent study demonstrated that in S1P3 null mice acute mus-
cle regeneration was enhanced and that genetic ablation of S1P3
inmdxmice produced a less severe dystrophic phenotype (Fortier
et al., 2013). Further studies are therefore required to clarify the
exact role of S1P3 in skeletal muscle regeneration.
Herr et al. (2003) have demonstrated that mutation in the gene
that encodes for the homolog of SPL generates Sply mutants in
fruit fly that do not catalyze S1P degradation and accumulate
S1P. In these mutants the thoracic flight muscles degenerate due
to the absence of fibers in the dorsal longitudinal muscles. These
findings highlight the importance of sphingolipid metabolism in
muscle homeostasis, crucial for adult muscle development and
integrity.
Presently, beside mammalian models to study muscular dys-
trophy including mouse, dog and cat, genetically tractable models
have been established in Danio rerio and Drosophila melanogaster
(Shcherbata et al., 2007). Very recently, a paper published by
Pantoja et al. (2013), demonstrated that suppression of wunen, an
homolog of lipid phosphate phosphatase 3, suppresses dystrophic
muscle phenotype measured by evaluation of correct localiza-
tion of the titin-homolog, projectin, in sarcomeres and functional
movements. The authors demonstrated that wunen suppression
acts through the elevation of S1P levels, since analogous findings
were obtained altering S1P levels genetically via down-regulation
of SPL or up-regulation of serine palmitoyl-CoA transferase, or
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pharmacologically by oral administration of SPL inhibitors. The
same authors have very recently demonstrated that an increase
of S1P levels via administration of an SPL inhibitor positively
affected acute muscle regeneration of dystrophic mdx mice. The
beneficial effects of S1P on increased muscle fiber size, force,
diminished fibrosis, and fat accumulation were linked to the abil-
ity of S1P of increasing the number ofmyogenic cells (Ieronimakis
et al., 2013).
The role of S1P2 in vivo in the early phases of regeneration
has been demonstrated recently by Germinario et al. (2012) after
injection of notexin in two mouse model of S1P2 deficiency: the
S1P2 null mice and wild-typemice systemically administered with
the S1P2 antagonist JTE-013. Indeed, the absence of S1P2 or its
blockade delayed the regeneration of skeletal muscle measured as
soleus CSA. Interestingly, the systemic administration of an anti-
S1P antibody, which induced a reduction of soleus fiber growth
in wild-type mice was ineffective in the absence of S1P2.
Microarray study revealed that during mouse skeletal muscle
regeneration following notexin injury, while sphk1 gene is upreg-
ulated at early time points, sgpl1 gene is induced several days post
injury (Loh et al., 2012). SPL is expressed at very low level in skele-
tal muscle at rest, while is up-regulated in response to ischemia
(Kumar and Saba, 2009) and radiation (Bandhuvula et al., 2011).
The specific requirement for SK1 to support muscle regeneration
and satellite cell recruitment has been demonstrated in SK1 null
mice. Interestingly the plasma of dystrophic mdx mice display
reduced S1P levels, comparable to that of SK1 null mice, probably
due to a significant up-regulation of sgpl1 rather than down-
regulation of sphK1 or sphK2 genes. Tetrahydroxybutylimidazole,
unspecific inhibitor of SPL, improved the number of regenerating
fibers in dystrophic muscles and satellite cell activation. The com-
bination of pharmacological inhibitors, S1PR antagonists and
plasmid constructs in vitro showed that S1P recruits satellite cells
through activation on S1PR2/Rho GTPase/STAT3 signaling axis
(Loh et al., 2012).
BIOLOGICAL ROLE OF S1P IN INSULIN RESPONSIVENESS OF
SKELETAL MUSCLE
Skeletal muscle plays a crucial role in the regulation of whole body
metabolism. In response to insulin, in fed condition, skeletal mus-
cle is responsible for glucose removal from the bloodstream thus
contributing to the majority of glucose disposal for the building-
up of glycogen. Since skeletal muscle utilizes the majority of body
glucose, reduced insulin responsiveness in skeletal muscle leads
to the development of metabolic syndrome (McGarry, 2002).
SK1/S1P axis has recently been implicated in the regulation of
glucose metabolism. In C2C12 myoblasts pharmacological inhi-
bition of SK1 reduced insulin-stimulated glucose uptake while its
overexpression mimicked in vivo insulin action. Moreover, over-
expression of SK1 gene reduced blood glucose level in diabetic
mice (Ma et al., 2007). In keeping with the role of S1P as insulin-
mimetic cue, a study has reported that in C2C12 myoblasts
S1P, through engagement of S1P2, produces a transient burst
of reactive oxygen species which is sensed by protein tyrosine
phosphatase-1B, the main negative regulator of insulin recep-
tor phosphorylation, which undergoes inhibition. This blockade
provokes a ligand-independent trans-phosphorylation of insulin
receptor and a strong increase in glucose uptake (Rapizzi et al.,
2009). This study appears to provide the possible mechanistic
explanation of the insulin-mimetic action of SK1 overexpression,
highlighting a feedback responsible for the sustained activation of
insulin receptor. Since in this study possible implications of S1P-
directed insulin signaling in diabetes were not established, future
studies are required aimed at clarifying whether impaired S1P sig-
naling contributes to the development of insulin resistance and
whether improvement of S1P/S1P2 signaling would be beneficial
for glucose disposal by skeletal muscle.
In addition to the role of elevated triacylglycerol levels in skele-
tal muscle for the development of insulin sensitivity (McGarry,
2002), a number of reports support the role of ceramide for
diminished insulin responsiveness. Taking into account that SK
plays a crucial role in the regulation of the relative levels of
ceramide/sphingosine and S1P, it will be of crucial interest in
the future to understand whether the biological effects observed
as consequence of SK overexpression are due to specific S1P-
induced signaling or rather to diminution of ceramide cellular
levels.
In this line, transgenic mice overexpressing SK1 display
improved insulin sensitivity compared to wild-type animal after
a 6 week high fat diet, due to increased SK activity in skeletal
muscle and decreased intracellular ceramide content (Bruce et al.,
2012). The same authors have demonstrated that daily treatment
with FTY720, that acts as functional antagonist of S1PR and has
been reported to inhibit the activity of ceramide synthase in vitro
(Berdyshev et al., 2009; Lahiri et al., 2009), for 6 weeks after an
high fat diet improved mice glucose tolerance, insulin uptake and
Akt phosphorylation through ceramide, diacylglycerol, and tria-
cylglycerol reduction in muscle (Bruce et al., 2013). Interestingly,
the expression levels of the enzymes involved in sphingolipid
metabolism were not altered.
It has been demonstrated that treatment with palmitate in
C2C12 myotubes increased S1P as consequence of increased
expression and activity of SK1 (Hu et al., 2009). Very recently,
in the context of free fatty acid oversupply it has been shown that
SK1 is regulated at transcriptional level by the transcription factor
PPARα in C2C12 cells (Ross et al., 2013). Moreover, specifically
in skeletal muscle palmitate treatment induced the expression of
IL-6 and its downstream signaling in a SK1- and S1P3-dependent
manner. IL-6 expression, which is up-regulated in diet-induced
obese mice, was attenuated in SK1 null mice. IL-6 produced by
skeletal muscle is the prototype of an emerging class of cytokines
named myokines which mediate the cross-talk between muscle
and other tissues. The role of IL-6 and its signaling in skeletal
muscle of obese mice remain unaddressed in this study. Since
several studies have reported that muscular IL-6 has a role in
metabolism rather than in inflammation, working as an energy
sensor and as a lipolytic factor (Pedersen and Febbraio, 2012), the
role of SK in the regulation of IL-6 expression and release by skele-
tal muscle should also be therefore further investigated in other
experimental settings.
CONCLUSION
Overall, the here reported experimental findings highlight the
fundamental role of S1P signaling axis in skeletal muscle biology.
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Future studies will confidently dissect in detail the molecular
mechanisms that regulate S1P metabolism and S1PR expression
in the various aspects of skeletal muscle biology and hopefully
they will bring to characterize the therapeutic potential of S1P
signaling pathway in skeletal muscle diseases.
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